Clinical trial / 2021
Daily n-3 fatty acid supplementation did not reduce cardiovascular events in elderly patients with recent myocardial infarction.
The OMEMI trial evaluated whether adding 1.8 g of n-3 PUFA (930 mg EPA and 660 mg DHA) daily versus corn oil placebo to standard of care reduced cardiovascular events over 2 years in patients aged 70 to 82 years with recent AMI. Among 1014 analyzed patients, the primary composite endpoint occurred in 21.4% (108/505) of the n-3 PUFA group and 20.0% (102/509) of the placebo group (HR 1.08 [95% CI, 0.82-1.41]; P=0.60). New atrial fibrillation occurred in 7.2% vs 4.0% (HR 1.84 [95% CI, 0.98-3.45]; P=0.06), and major bleeding occurred in 10.7% vs 11.0% (P=0.87). The authors concluded they could not detect a reduction in clinical events with 1.8 g n-3 PUFAs daily for 2 years in this population.
- Study type
- Multicenter randomized controlled trial
- Who was studied
- 1027 patients aged 70 to 82 years with recent (2-8 weeks) acute myocardial infarction
- What was measured
- Composite of nonfatal AMI, unscheduled revascularization, stroke, all-cause death, and heart failure hospitalization after 2 years
THE PAPER
Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction: A Randomized, Controlled Trial.
Kalstad AA, Myhre PL, Laake K, Tveit SH, Schmidt EB, Smith P, Nilsen DWT, Tveit A, Fagerland MW, Solheim S, Seljeflot I, Arnesen H, OMEMI Investigators. Circulation, 2021.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.